TY  - GEN
AU  - Smith,Peter K
AU  - Shernan,Stanton K
AU  - Chen,John C
AU  - Carrier,Michel
AU  - Verrier,Edward D
AU  - Adams,Peter X
AU  - Todaro,Thomas G
AU  - Muhlbaier,Lawrence H
AU  - Levy,Jerrold H
TI  - Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials
SN  - 1097-685X
PY  - 2011///0819
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Anti-Inflammatory Agents
KW  - administration & dosage
KW  - Antibodies, Monoclonal
KW  - Antibodies, Monoclonal, Humanized
KW  - Cardiopulmonary Bypass
KW  - Chi-Square Distribution
KW  - Complement C5
KW  - antagonists & inhibitors
KW  - Coronary Artery Bypass
KW  - adverse effects
KW  - Coronary Artery Disease
KW  - immunology
KW  - Double-Blind Method
KW  - Europe
KW  - Female
KW  - Humans
KW  - Infusions, Intravenous
KW  - Kaplan-Meier Estimate
KW  - Male
KW  - Middle Aged
KW  - Myocardial Infarction
KW  - North America
KW  - Proportional Hazards Models
KW  - Risk Assessment
KW  - Risk Factors
KW  - Single-Chain Antibodies
KW  - Time Factors
KW  - Treatment Outcome
N1  - Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/j.jtcvs.2010.08.035
ER  -